Navigation Links
Efficacy and Safety Data from Phase 2B Trials of Janssen's Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
Date:11/10/2012

tment option for people living with advanced hepatitis C if proven in advanced trials."

Simeprevir, an investigational NS3/4A protease inhibitor jointly developed by Janssen and Medivir, is currently in Phase 3 studies as a once-daily treatment taken in combination with pegylated interferon and ribavirin for the treatment of genotypes 1 and 4 chronic hepatitis C. It is also being studied in separate Phase 2 trials with other direct-acting antiviral agents as part of interferon-free regimens, with and without ribavirin. This includes a recently initiated Phase 2a trial of an interferon-free regimen with simeprevir and TMC647055, Janssen's non-nucleoside polymerase inhibitor (NNI) currently in development for hepatitis C.

"We are encouraged by these data, which show sustained viral response and tolerability in both treatment-naive and more challenging-to-cure patients," said Maria Beumont, M.D., Medical Leader for simeprevir, Janssen Research & Development. "We look forward to further evaluating the utility of simeprevir in combination with other agents for the treatment of hepatitis C."

About the PILLAR & ASPIRE Trials  
In the two international, Phase 2b, randomized, double-blind, placebo-controlled studies, patients were either treatment naive (PILLAR) or treatment experienced (ASPIRE), and received pegylated interferon and ribavirin alone or in combination with once-daily simeprevir. In PILLAR, 309 treatment-naive hepatitis C patients received either 75 or 150 mg of once-daily simeprevir for 12 or 24 weeks plus pegylated interferon and ribavirin for 24 or 48 weeks depending on their response to treatment. In ASPIRE, 396 treatment-experienced patients received either 100 or 150 mg of once-daily simeprevir for 12, 24 or 48 weeks plus pegylated interferon and ribavirin for 48 weeks.

The post hoc analyses of PILLAR and ASPIRE presented at AASLD (abstracts 83 and 769) evaluated only patients receiving 150 m
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. JAMA Study Demonstrates Efficacy of Life Technologies Lung Cancer Test in Detecting Early Metastases, Supports Screening for Lung Cancer
2. Optimization of Comparative Efficacy Trials
3. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
4. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
5. MedQIA unique CAD algorithm for Quantitation of lung involvement in diffuse lung disease used as treatment efficacy end point in study to be reported at the ERS Annual Conference in Vienna, Austria: September 1-5, 2012
6. Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis
7. FDAnews announces Fifth Annual Risk Management & Drug Safety Summit
8. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
9. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
10. Compounding Pharmacy Safety: Dr. Paul Savage Published in IMJC Post #Meningitis Outbreak
11. Kansas Car Umbrella Encouraged By New Safety Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015 Research and Markets ( ... "Radiation Therapy Equipment - Global Strategic Business Report" ... analyzes the worldwide markets for Radiation Therapy Equipment in ... Treatment Planning Systems, and Radiation Therapy Simulator. The report ... Canada , Japan , ...
(Date:2/26/2015)... Feb. 26, 2015 Integrity Applications, Inc. (OTCQB: ... ® model DF-F, a noninvasive  device that tracks blood ... , Ph.D., will head its new scientific advisory board ... the field of Diabetes research, monitoring and treatment. ... been Chief Executive Officer and Head, Business Development of ...
(Date:2/26/2015)... BURNIE, Md. , Feb. 26, 2015 /PRNewswire/ ... recruitment solutions for the clinical research industry, is ... Karen Welch as a Project Manager, adding ... Photo - http://photos.prnewswire.com/prnh/20150225/177750 ... Manager with a demonstrated ability to successfully lead ...
Breaking Medicine Technology:Radiation Therapy Equipment - Global Strategic Business Report 2015-2020: Linear Accelerator, Treatment Planning Systems, and Radiation Therapy Simulator 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 3Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 4CSSi's Continued Growth Brings Talented New Hire - Karen Welch Welcomed as Project Manager 2
... 2011 Pharmaceutical Care Management Association (PCMA) President and ... Florida Governor Rick Scott,s Medicaid savings proposal: ... spending in Medicaid, which is a big problem when ... ,fee-for-service, approach, Florida Medicaid pays drugstores much more than ...
... 8, 2011 Dynatronics Corporation (Nasdaq: DYNT ) ... months ended December 31, 2010 during the morning of Monday, ... conference call for investors later that day at 1:30 p.m. ... in participating should call (800) 926-7431 and use access code: ...
Cached Medicine Technology:
(Date:2/27/2015)... February 27, 2015 Developers of FCPX ... a new transition plugin for Final Cut ... “TransComic gives users total control over comic book ... Christina Austin, CEO of Pixel Film Studios. “TransComic was ... an easy interface.” , Transitions from one comic frame ...
(Date:2/26/2015)... February 27, 2015 Wireless ... management services, and one of the founders of ... engaged business development firm The Endurance Group to ... Analytics’ latest iteration of the CLEAN Platform™ (Communications ... The Endurance Group, based in Yarmouth, ME ...
(Date:2/26/2015)... Guide to FDA Medical Device Regulations ... Whether a manufacturers needs to convince the FDA to ... or implement UDI across a family of high-risk implantable ... most up-to-date, latest FDA regulations available. ... Regulations is an FDAnews best-seller. , The 2015 Guide ...
(Date:2/26/2015)... 27, 2015 New location, same ... to announce it is accepting new patients at ... Chesapeake, Va. , The new location opened its ... and rehabilitation programs, including the following programs: , ... orthopedic care, -Vestibular rehabilitation, -Neurological rehabilitation, -Balance and ...
(Date:2/26/2015)... Dallas, Texas (PRWEB) February 27, 2015 ... Sodium Benzoate Industry is a professional and in-depth ... Sodium Benzoate industry with a focus ... in Sodium Benzoate market research are Wuhan Youji, ... Sonef, CG Chemikalien, MOLLER CHEMIE and W.ULRICH. , ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Released a New Transition Plugin Entitled TransComic Exclusively for Final Cut Pro X Users 2Health News:Wireless Analytics Engages The Endurance Group to Promote Upcoming CLEAN Platform™ 4.0 Launch 2Health News:Wireless Analytics Engages The Endurance Group to Promote Upcoming CLEAN Platform™ 4.0 Launch 3Health News:FDAnews Bestseller Updated: Guide to FDA Medical Device Regulations — 2015 Edition 2Health News:Tidewater Physical Therapy Accepting New Patients at Relocated Battlefield Clinic 2Health News:Global Sodium Benzoate Industry Analysis Report 2015-2020 Now at DeepResearchReports.com 2Health News:Global Sodium Benzoate Industry Analysis Report 2015-2020 Now at DeepResearchReports.com 3
... at your computer screens is bad for the eyes since it ... irritation and tearing // . Researchers at the Ohio State University ... at risk for dry eye. ,"People tend to squint ... squinting makes the blink rate go way down," said lead researcher ...
... by mothers who are about to deliver premature babies, as ... their survival rates are lower // . Annie Janvier and ... records the records of about 72 babies who ran the ... period, and came to the conclusion that the conversations that ...
... and his colleagues from Toronto General Hospital Sleep Research ... have an increased risk of developing heart attacks // ... stroke and treating their sleeping disorder can reduce the ... 1,475 people aged between 30 and 60 and grouped ...
... The grassroots leadership with regard to combating AIDS is being ... award. The award will be presented to five people in ... conference in Toronto August 13-18. The five will ... care, treatment and support for AIDS patients, work on stigma ...
... can be triggered by exposure to endotoxins in the ... Critical Care Medicine study. Humidifiers, pests, dust, pets, and ... according to the University of Iowa’s Dr. Peter S. ... homes selected to represent the demographic characteristics of the ...
... took a pledge to abstain from promiscuous sex on 1 ... the developing nations // and ignorance with regard to ... Envoy of the U.N Stephen Lewis, has called upon the ... ,The AIDS scourge is continuing to take a heavy ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: